Trial Profile
A Phase I, Multicenter, Dose-Escalation Trial Evaluating the Safety of Allogeneic AMI MultiStem in Patients With Acute Myocardial Infarction
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Invimestrocel (Primary)
- Indications Myocardial infarction
- Focus Adverse reactions
- 07 Aug 2013 New trial record
- 06 Aug 2013 Results were published in Circulation Research in January 2012, according to an Athersys media release.